loader2
Login Open ICICI 3-in-1 Account

Torrent Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Torrent Pharmaceuticals Ltd. 07 Nov 2025 17:48 PM

Q2FY26 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.

Pharmaceuticals company Torrent Pharmaceuticals announced Q2FY26 results

  • Revenue at Rs 3,302 crore against 2,889 crore during Q2FY25, up by 14% YoY.
  • Op. EBITDA at Rs 1,083 crore against 939 crore during Q2FY25, up by 15% YoY.
  • Op. EBITDA margin at 32.8%; Gross Margin: 76%.
  • Net Profit after tax at Rs 591 crore against 453 crore during Q2FY25, up by 30% YoY.

Result PDF

Pharmaceuticals company Torrent Pharmaceuticals announced Q1FY26 results

  • Revenue at Rs 3,178 crore; grew by 11% YoY
  • India revenues at Rs 1,811 crore were up by 11% led by outperformance in focus therapies.
  • Brazil revenues at Rs 218 crore, were up by 11%.
  • Germany revenues at Rs 308 crore, were up by 9%
  • US business revenues at Rs 308 crore, were up by 19%.
  • Op. EBITDA at Rs 1,032 crore, up by 14% YoY
  • Op. EBITDA margin at 32.5%; Gross Margin: 76%
  • Includes acquisition related one-off expenses of Rs 15 crore. Op. EBITDA adjusted for these one-offs is 1,047 crore, with a margin of 32.9%
  • Net Profit after tax at Rs 548 crore, up by 20% YoY.
  • R&D spend stood at Rs 157 crore compared to Rs 135 crore up 16%

Result PDF

Pharmaceuticals company Torrent Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue at Rs 2,959 crore; grew by 8% YoY.
  • Gross Margin: 75.3%, Op. EBITDA margin at 32.6%.
  • Op. EBITDA at Rs 964 crore, up by 9% YoY.
  • Net Profit after tax at Rs 498 crore, up by 11% YoY.
  • R&D Spend was Rs 150 crore (5.1%) vs Rs 139 crore (5.1%) — up 8% YoY

FY25 Financial Highlights:

  • Revenue reached Rs 11,516 crore vs Rs 10,728 crore — up 7% YoY
  • Gross Profit grew to Rs 8,740 crore (75.9%) from Rs 8,042 crore (75.0%) — up 9% YoY
  • Operating EBITDA increased to Rs 3,721 crore (32.3%) from Rs 3,368 crore (31.4%) — up 10% YoY
  • PAT (adjusted) came in at Rs 1,911 crore (16.6%) vs Rs 1,656 crore (15.4%) — up 15% YoY
  • R&D Spend rose to Rs 581 crore (5.0%) vs Rs 527 crore (4.9%) — up 10% YoY

Result PDF

Pharmaceuticals company Torrent Pharmaceuticals announced Q3FY25 results

  • Revenue at Rs 2,809 crore grew by 3%
  • Gross Margin: 76.0%, Op. EBITDA margin at 32.5%.
  • Op. EBITDA at Rs 914 crore, up by 5%.
  • Net Profit after tax at Rs 503 crore, up by 14%
  • No insulin CMO sales in the quarter. Dispatches restarted from January 2025.
  • During the quarter, BRL depreciated by 17% YoY.
  • Underlying revenue growth adjusted for above transient impact is 7% and Operating EBITDA growth is 12%

Result PDF

Pharmaceuticals company Torrent Pharmaceuticals announced Q2FY25 results

  • Revenue at Rs 2,889 crore grew by 9%, compared to Rs 2,660 during Q2FY24.
  • Gross pprofit: Rs 2,211 crore change 11%, Operating EBITDA margin at 32.5%.
  • Operating EBITDA at Rs 939 crore, compared to Rs 825 crore during Q2FY24, change 14%.
  • Net Profit after tax at Rs 453 crore, compared to Rs 386 crore during Q2FY24, change 17%.
  • Insulin revenues were impacted this quarter due to scheduled shutdown taken in the month of August for maintenance activities. The facility will be released for manufacturing in December. Shortfall is significantly planned to be recovered in Quarter 4 of this year and consequently there will not be any impact on a full year basis.
  • Adjusted for the above, the underlying revenue growth for the quarter is 10% with Operating EBITDA growth at 16%.

Result PDF

Pharmaceuticals company Torrent Pharmaceuticals announced Q1FY25 results:

  • Revenue at Rs 2,859 crore grew by 10%
  • Gross Margin: 75.7%, Op. EBITDA margin at 31.6%, Growth: 14%
  • Net Profit after tax at Rs 457 crore, up by 21%
  • Other expenses include one-off expenses of Rs 20 crore (in international business)
  • Adjusted for such one-off expenses, the underlying Op. EBITDA is Rs 924 crore and Op. EBITDA margin at 32.3%

Result PDF

Torrent Pharmaceuticals announced Q3FY24 results:

Financial Performance for Q3FY24:

  • Revenue: Rs 2,732 crore, indicating a 10% increase.
  • Gross Margin: 75%, maintaining a stable position in the market.
  • Operational EBITDA: Rs 869 crore, experiencing a 20% growth.
  • Exceptional Items: Gained net proceeds of Rs 88 crore from the sale of a US facility.
  • Net Profit After Tax (PAT): Rs 443 crore, marking a significant 52% surge.
  • Research & Development (R&D) Spend: Rs 127 crore, reaffirming the company's commitment to innovation.
  • Debt Equity Ratio: A ratio of 0.53, indicating a moderate level of debt in comparison to equity.
  • Debt Service Coverage Ratio: At 2.21, suggesting the company's ability to service its debt is well-managed.
  • Interest Service Coverage Ratio: Standing at 9.08, showing a strong ability to meet interest expenses.
  • Net Profit Margin: The net profit margin stood at 16%, representing the profitability from the revenue earned.

Country-wise Performance for Q3FY24:

  • India: Revenues reached Rs 1,415 crore, up by 12%, outperforming the market in focus therapies.
  • Brazil: Reported revenues of Rs 312 crore, growing by 26%, with constant currency revenues up by 17%.
  • Germany: Achieved revenues of Rs 270 crore, increasing by 12%, with constant currency revenues rising by 6% due to tender wins.
  • United States: US business revenues saw a slight decrease of 6% to Rs 274 crore, with constant currency revenues down by 7%, affected by a lack of new product launches.

 

Result PDF

Torrent Pharmaceuticals announced Q2FY24 results:

1. Revenues from India: In Q2FY24, Torrent Pharmaceuticals generated revenues of Rs 1,444 crore from its operations in India. This represents a growth of 18% compared to the same period last year.

2. Revenues from the United States: The company reported revenues of Rs 248 crore from its operations in the United States during Q2FY24. This reflects a decline of 15% compared to the corresponding quarter of the previous fiscal year.

3. Revenues from Germany: Torrent Pharmaceuticals generated revenues of Rs 266 crore from its operations in Germany in the Q2FY24. This indicates a growth of 21% compared to the same period last year.

4. Revenues from Brazil: The company reported revenues of Rs 252 crore from its operations in Brazil during Q2FY24.. This represents a substantial growth of 36% compared to the corresponding quarter of the previous fiscal year.

5. Revenues from Other Countries: Torrent Pharmaceuticals generated revenues of Rs 280 crore from its operations in other countries during the Q2FY24. This reflects a growth of 17% compared to the same period last year.

6. Other Revenues: The company reported revenues of Rs 170 crore from other sources during Q2FY24.

7.Overall, Torrent Pharmaceuticals reported total revenues of Rs 2,660 crore in Q2FY24, reflecting a growth of 16% compared to the same period last year.
 

 

 

Result PDF

Torrent Pharmaceuticals announced Q4FY23 results:

  • Q4FY23:
    • Revenue at Rs 2,491 crore up by 17%
    • Gross margins: 72%; Op. EBITDA margins: 29.2%
    • Op. EBITDA at Rs 727 crore was up by 30%
    • Profit after tax at Rs 287 crore
  • FY23:
    • Revenue at Rs 9,620 crore up by 13%
    • Gross margins: 71%; Op. EBITDA margins: 29%
    • Op. EBITDA at Rs 2,842 crore was up by 17%
    • Profit after tax at Rs 1,245 crore

 

 

Result PDF

Torrent Pharmaceuticals announced Q3FY23 results:

  • Revenue at Rs 2,491 crore, up by 18%
  • Gross margins: 71%; Op EBITDA margins: 29.1%
  • Op EBITDA at Rs 724 crore, up by 35%
  • Net profit after tax at Rs 283 crore, up by 14%
  • India:
    • India revenues at Rs 1,259 crore grew by 17% and included revenue from the integration of Curatio Healthcare
    • As per AIOCD secondary data, Torrent’s growth for the quarter was 12% vs IPM growth of 12%
    • Field force has been further expanded and MR strength now stands at 5,300, including Curatio divisions
    • For YTD Dec FY23, revenues were Rs 3,728 crore, up by 15%
  • Brazil:
    • Brazil revenue at Rs 248 crore, up by 36%
    • Constant currency revenue at Rs 159 million, up by 17%
    • As per secondary data set, Torrent’s growth is 19% vs BGx market growth of 13% for the quarter ended in November 22
    • Growth was aided by performance of top brands and market share gain and strong momentum in the generic segment
    • For YTD Dec FY23, revenues were Rs 617 crore, up by 26% (Constant currency revenue: Rs 397 million, up by 12%)
  • Germany:
    • Germany revenue at Rs 241 crore up by 1%
    • Constant currency revenue was Euro 29 million, up by 4%
    • Sequential recovery in Germany complemented by new tenders and growth of OTC segment
    • For YTD Q3FY23, revenues were Rs 675 crore, down by 10% (Constant currency revenue: Euro 82 million).
  • United States:
    • US revenue at Rs 291 crore, up by 24%
    • Constant currency revenue at US$ 35 million, up by 13%
    • As on December 31, 2022, 48 ANDAs were pending approval with USFDA and 3 tentative approvals were received. During the quarter, 1 ANDAs was filed & 1 ANDAs was approved
    • For YTD Dec FY23, revenues were Rs 882 crore, up by 12% (Constant currency revenue: US$ 111 million, up by 5%)

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app